Mechanism of Nuclear Hormone Receptors in Cancer II
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".
Deadline for manuscript submissions: closed (25 February 2024) | Viewed by 1934
Special Issue Editors
Interests: hormone-dependent cancers; steroid hormone receptors; estrogen; androgen
Special Issues, Collections and Topics in MDPI journals
Interests: estrogen receptor; breast cancer; osteoporosis; vitamin K
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The relationship between hormones and cancer has a long history that can be traced back to the 19th century when Dr. Beatson treated a breast cancer patient by ovariectomy in 1896. In 1941, Dr. Huggins performed orchidectomy and administered estrogen to a prostate cancer patient, which led to his receipt of the Nobel Prize in 1966. In 1971, tamoxifen came into clinical use as an endocrine therapy for breast cancer. Interestingly, the clinical use of tamoxifen preceded the molecular cloning of the estrogen receptor in 1986. Now, we understand the importance of estrogen receptors and the androgen receptor as transcription factors in the pathogenesis of breast cancer and prostate cancer. Investigations of novel mechanisms of these receptors, such as nongenomic actions or post-transcriptional modifications, are ongoing.
The estrogen receptors and the androgen receptor belong to the nuclear receptor superfamily. Several members of this superfamily are classified as steroid or other hormone receptor subfamilies. In relation with malignancies, their ligands including glucocorticoids and retinoic acid are clinically used for lymphoma and leukemia. In addition, it has been suggested that nuclear receptors without corresponding steroid ligands or orphan nuclear receptors whose endogenous ligands have not been discovered are involved in the mechanism of cancer development.
This Special Issue aims to summarize current knowledge on the nuclear hormone receptors in relation to cancer biology. We invite experts in this field to submit original research papers or reviews on the various nuclear receptors in human cancers. A wide range of studies, from basic to clinical research, are welcome.
Prof. Dr. Satoshi Inoue
Dr. Kotaro Azuma
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hormone
- nuclear receptor
- genetics
- transcription
- RNA regulation
- epigenetics
- protein modification
- cancer
- metabolomics
- breast
- prostate
- uterus
- ovary
- testis
- endocrine-related cancer
- hormone therapy
- refractory cancer
- CRPC
